Triple-action treatment for improved outcomes for slow-healing leg ulcers, pressure sores and diabetic ulcers

在英国，每年大约有100万患者接受复杂的、缓慢愈合的腿部溃疡、糖尿病溃疡或压疮的治疗。他们需要在家里或在当地诊所更换伤口敷料，有时每周一次，有时每天一次。该项目的目标是开发一种敷料形式的伤口治疗方法，解决护理这些复杂的不愈合伤口的主要挑战，改善患者的生活，并节省NHS每年在伤口护理上花费的大约50亿英镑中的一部分。随着英国人口老龄化、肥胖症的增加和2型糖尿病的流行，越来越需要在家中或初级保健机构治疗缓慢愈合的腿部溃疡、压疮和糖尿病足溃疡。该项目结合了多种优点，可以在一次治疗中愈合伤口，敷料使用时间长，可以在社区环境中使用。伤口通常处于慢性炎症状态，并且可能有细菌生物膜减慢或停止愈合过程。到目前为止，我们的研究表明，我们可以在一种敷料中结合一种抗炎化合物，这种化合物可以加速伤口愈合，减少伤口的复发感染，并从伤口中吸收大量液体。这有望成为解决上述社会需求的突破性解决方案。Io-Cyte有限公司（[www.io-cyte.co.uk][0]）是一家新的伤口护理技术公司，已经从Xiros有限公司分拆出来，Xiros有限公司是一家专门从事骨科的老牌公司。这项工作来自Xiros生物材料研究机构的研究。Io-Cyte将开发并推向市场的产品是基于我们已经申请的专利。[0]: http://www.io-cyte.co.uk/

Around one million patients in the UK are treated every year for complex, slow-healing leg ulcers, diabetic ulcers or pressure sores. They need their wound dressings changed at home or at their local practice, sometimes once a week and sometimes every day. The goal of the project is to develop a wound treatment in dressing form that addresses the major challenges in caring for these complex non-healing wounds, improving the lives of patients and saving some of the estimated £5bn per year that the NHS spends on wound care. With the UK's aging population, the rise in obesity and the epidemic of Type 2 diabetes there is increasing need to treat slow-healing leg ulcers, pressure sores and diabetic foot ulcers at home or in primary care.This project combines multiple benefits for healing wounds in one treatment in a dressing with a long wear time that can be used in community setting. Wounds are often "stuck" in a chronically inflamed state and are likely to have bacterial biofilms that slow down or stop the healing process. Our research carried out to date shows we can combine in a single dressing an anti-inflammatory compound that can speed up wound healing with an ability to reduce the recurring infections in wounds and absorb large amounts of fluid from the wound. This promises to be a break-through solution for the societal needs identified above.Io-Cyte Ltd ([www.io-cyte.co.uk][0]) is a new woundcare technology company that has been spun-out from Xiros Ltd, an established company specialising in orthopaedics. The work comes from research done in Xiros' biomaterials research facility. The product that Io-Cyte will develop and bring to the market is based on the patents that we have filed.[0]: http://www.io-cyte.co.uk/